Macular Degeneration clinical trials

Explore recruiting macular degeneration clinical trials.

Recruiting macular degeneration studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Macular Degeneration trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Aflibercept 8mg for high-frequent Faricimab and prior Aflibercept 2mg treated Neovascular age-related macular degeneration: a monocenter, single-arm, open-label extension study (A-FAN)

Austria

Phase III and phase IV (Integrated) EU CTIS Study details

An Open Label Study to Determine the Long Term Safety, Tolerability and Biological Activity of SAR422459 in Patients with Stargardt’s Macular Degeneration

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Add-Aspirin: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non metastatic solid tumours.

Ireland

Therapeutic confirmatory (Phase III) EU CTIS Study details

The Sahlgrenska Anti-VEGF (SAHLVE) Study - a Prospective Randomized Double-blind Comparison of Bevacizumab and Aflibercept in Patients With Neovascular Age-related Macular Degeneration

Sweden

Therapeutic exploratory (Phase II) EU CTIS Study details

ReNEW: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects who have Dry Age-Related Macular Degeneration (Dry AMD)

Italy, Hungary, Germany, Czechia, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

Faricimab for high-frequent Aflibercept treated Neovascular age-related macular degeneration: a monocenter, randomized, double-masked comparator-controlled study (FAN study)

Austria

Phase III and phase IV (Integrated) EU CTIS Study details

Macular Degeneration trials by city

Macular Degeneration in Toronto Macular Degeneration in Vancouver Macular Degeneration in Montreal Macular Degeneration in Calgary Macular Degeneration in Edmonton Macular Degeneration in Ottawa Macular Degeneration in Winnipeg Macular Degeneration in Quebec City Macular Degeneration in Hamilton Macular Degeneration in Kitchener Macular Degeneration in London Macular Degeneration in Halifax Macular Degeneration in New York Macular Degeneration in Los Angeles Macular Degeneration in Chicago Macular Degeneration in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease